Hypoxic-Ischemic Encephalopathy
2
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Mononuclear TherapeuticsChina - Hong Kong
1 program1
autologous umbilical cord bloodPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
PharmazzNormal Saline along with standard treatment
Mononuclear Therapeuticsautologous umbilical cord blood
Mission TherapeuticsUmbilical Cord Milking
Clinical Trials (3)
Total enrollment: 440 patients across 3 trials
Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy
Start: Sep 2023Est. completion: Dec 202640 patients
Phase 2Recruiting
Feasibility and Safety of Umbilical Cord Blood Transfusion in the Treatment of Neonatal Cerebral Ischemia and Anemia
Start: Apr 2018Est. completion: Dec 2020
Phase 1Unknown
Role of Umbilical Cord Milking in the Management of Hypoxic-ischemic Encephalopathy in Neonates
Start: Jan 2018Est. completion: Jul 2022400 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 440 patients
3 companies competing in this space